July 13, 2021
FOR IMMEDIATE RELEASE
Contact: Joanie Manzo
Director, Marketing & Physician Services
OHC’s cancer experts are evaluating a new therapy in a clinical trial for relapsed or refractory B-cell non-Hodgkin lymphoma ([r/r] B-NHL). A patient received an allogeneic CAR T-cell therapy at OHC’s Kenwood office. This treatment, Caribou Biosciences’ CB-010, has the potential to offer several benefits to B-NHL patients whose cancer has relapsed or not responded to prior treatments.
Three years ago, OHC’s cancer experts represented the first adult cancer group in the region to introduce the revolutionary immunotherapy called autologous chimeric antigen receptor (CAR) T-cell therapy (CAR-T) for adults with aggressive blood cancers. Autologous CAR T-cell therapies use a patient’s own T-cells that are genetically engineered to prepare the CAR T-cell therapy which is then given back to the same patient. T-cells are an important part of the immune system that can kill cancer cells in the body.
OHC is participating in Caribou Biosciences’ ANTLER phase 1 study to evaluate a new type of cell therapy, called allogeneic CAR T-cell therapy, for multiple subtypes of r/r B-NHL. Allogeneic means that the CAR T-cells are derived from a healthy donor rather than taken from the patient. The healthy donor’s T-cells are genetically modified for administration to a cancer patient in a universal “off-the-shelf” manner that reduces the waiting time for the patient compared to autologous CAR T-cell therapy and may offer additional patient benefits such as those described below. The healthy donor T-cells are genetically engineered to contain a CAR. The CAR is designed to bind to a certain protein on tumor cells, resulting in the targeting of CAR T-cells to kill malignant cells in the patient.
“We are very excited to have access to this ‘off-the-shelf’ investigational product using healthy donor T-cells as another option to the patient’s own T-cells,” said OHC’s James H. Essell, MD, a medical oncologist, hematologist, blood and marrow transplant specialist, and principal investigator on the study. “Elimination of the wait time for access to CAR-T therapy for cancer patients is a tremendous benefit.”
Currently, it can take three to four weeks to modify a patient’s own T-cells in preparation for treatment, while the ANTLER phase 1 trial ensures availability of the CAR T-cell therapy material immediately after patient enrollment in the trial.
In addition to quick access to an inventory of healthy donor-derived CAR T-cells, this investigational product has the following potential benefits:
- Extended CAR T-cell persistence and durability of antitumor activity (compared to those without sophisticated engineering)
- Eliminates T-cell receptor expression to reduce the risk of graft versus host disease
- Prevention of T-cell exhaustion (which is sometimes seen with T-cells from a patient who has received years of chemotherapy)
The Caribou study will consist of two parts with an estimated enrollment up to 50 patients across multiple centers in the United States. OHC leads the charge in being the first practice to treat a patient as a participant in Caribou Biosciences’ ANTLER phase I clinical trial.
Despite advances in immunotherapy, too few patients benefit from today’s approved treatments. OHC believes that cancer research is essential to help avoid treatment delay, improve access to revolutionary treatments, and, in turn, provide more opportunity for remission. “Our hope is to treat patients sooner and avoid unnecessary delay in treatment, thereby increasing their potential survival rate,” said Dr. Essell.
OHC (Oncology Hematology Care) has been fighting cancer on the front lines for more than 35 years. We are the region’s leading experts in the treatment of nearly every form of adult cancer and complex blood disorder. OHC offers the latest medical, gynecologic and radiation therapy, and is always seeking better treatment options through its nationally recognized cancer research and clinical trials program. OHC is the first – and most experienced – independent adult cancer practice to offer the ground-breaking CAR-T therapy for adults. OHC is certified by the American Society for Clinical Oncology in the Quality Oncology Practice Initiative Certification Program and is one of only a select few cancer practices nationally to be accepted to participate in the Oncology Care Model, part of The Center for Medicare and Medicaid Innovation Center. At its heart, our approach to cancer care is simple – to surround you with everything you need so you can focus on what matters most: beating cancer. For more information about OHC, or a second opinion, call 1-888-649-4800 or visit ohcare.com.Comments (0)